News | May 04, 2026
Bristol Myers Squibb begins 2026 with growth momentum
The company’s Growth Portfolio delivered $6.2 billion in revenue
The company’s Growth Portfolio delivered $6.2 billion in revenue
The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 3 to 6 against recommending camizestrant in combination with a CDK4/6 inhibitor
The move puts a spotlight on one of psychiatry’s most persistent clinical challenges: misdiagnosis and delay
Stroke is the second-leading cause of death and the third-leading cause of disability worldwide
Under the terms, Arcellx shareholders received $115 per share in cash plus a non-transferable contingent value right
The 4,000-square-foot facility is designed as a hands-on hub where customers can work directly with scientists and engineers
But acquisition charges drag earnings into loss
Leading orthopaedic experts call for equitable insurance coverage to patients for accessing advanced, precision-driven joint replacement technologies
Study introduces structured, condition-specific emergency coding system to improve coordination, response time, and patient safety in tertiary care hospitals
Subscribe To Our Newsletter & Stay Updated
